53
Participants
Start Date
May 31, 2015
Primary Completion Date
September 11, 2018
Study Completion Date
September 11, 2018
bimiralisib
60 mg or 80 mg bimiralisib per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
Weill Cornell Medicine, New York
Clinical Center Kragujevac, Kragujevac
University Clinical Center Sarajevo, Sarajevo
University Clinical Center Republic of Srpska, Banja Luka
Insitute Curie, Saint-Cloud
Institute for Oncology and radiology of Serbia, Belgrade
Clinical Center Nis, Niš
Univeristy Hospital Haifa, Haifa
Royal Marsden NHS Foundation Trust, London
University College Hospital London, London
Guy's Hospital, London
Churchill Hospital, Oxford
Lead Sponsor
Collaborators (2)
University College London Hospitals
OTHER
Churchill Hospital
OTHER
Royal Marsden NHS Foundation Trust
OTHER
University of Haifa
OTHER
Weill Medical College of Cornell University
OTHER
Institut Curie
OTHER
University Clinical Center, Sarajevo
UNKNOWN
Clinical Center Kragujevac
OTHER
Clinical Center Nis, Nis
UNKNOWN
Institute for Oncology and Radiology Serbia, Belgrade
UNKNOWN
University Clinical Centre of Republic of Srpska
OTHER
PIQUR Therapeutics AG
INDUSTRY